| HOME >> BIOLOGY >> TECHNOLOGY |
DURHAM, N.C., Dec. 16 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced that the National Institutes of Health (NIH) have awarded the company a biodefense grant in excess of $850,000.
The purpose of the grant is to advance the development of safe and effective medical treatments that mitigate pulmonary injury arising from inhalation of radioactive particles using Parion's Radiation and Bioterrorism Countermeasures Platform. Parion will utilize the funding in a series of studies to evaluate the benefits of their lead compound, CF-552, combined with hypertonic saline, to increase removal of inhaled radioactive particles from the lungs. In previous clinical studies, treatment with CF-552 increased clearance of non-hazardous, radio-labeled particles from the lungs of healthy volunteers, as compared to vehicle alone. A portion of the research will be conducted by the Lovelace Respiratory Research Institute (LRRI), a not-for-profit research institute located in Albuquerque, New Mexico.
"This award represents an important step to help us demonstrate the capacity of our novel ENaC inhibitor technology to treat radiation and bio-terror threats," said Paul Boucher, Senior Director, Finance and Business at Parion. "We look forward to demonstrating the utility of our compound to provide a novel medical countermeasure for the prevention of radiation-induced lung injury following a nuclear incident."
ENaC inhibitors are therapeutic agents that maintain and stimulate
hydration on the body's mucosal surfaces, including those on the lung, mouth,
nose, eye and gastrointestinal tract. Maintaining the hydration of mucosal
airway surfaces addresses the fundamental problem that produces infections in
both acquired and genetic forms of chronic lung disease, such as c
'/>"/>
| SOURCE Parion Sciences Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
2. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
3. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
4. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
5. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
8. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
9. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
10. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
11. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |